What you should know:
– Click on Therapeutica leader in prescription digital therapeutics (DTx), today announced the acquisition key assets of Better therapies.
– Click's expansion into cardiometabolic diseases follows successful efforts to develop DTx in other areas, including migraine prevention, depression, schizophrenia and opioid use disorders.
Strengthening the DTx pipeline
The acquisition includes several key Better Therapeutics assets:
- AspyreRx (BT-001): The first DTx cleared by the FDA for type 2 diabetes.
- BT-004: A DTx with breakthrough device designation from the FDA for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
- BT-002: A DTx designed to reduce blood pressure in patients with hypertension.
- BT-003: A DTx focused on reducing LDL cholesterol in patients with hyperlipidemia.
This strategic acquisition significantly expands Click's DTx portfolio, complementing its existing offerings in psychiatry, CNS and pain management. It also strengthens their position in the rapidly growing market for treatments for obesity and cardiometabolic diseases.
A personalized approach to weight management
Click's existing DTx solutions focus on psychiatry, CNS and pain disorders. By integrating Better Therapeutics' assets, Click immediately gains traction in the rapidly growing cardiometabolic space, complementing its current offerings.
Click highlights the importance of personalized treatment plans for obesity, a complex chronic disease. Their goal is to develop a best-in-class DTx solution that combines:
- Behavioral therapy: Leverage Better Therapeutics' clinically validated approach, perfected over nine years.
- AI-powered platform: The Click platform uses advanced engagement techniques and proprietary digital mechanisms to fight the disease.
- Medication integration: DTx will be optimized to work seamlessly with obesity and diabetes medications like GLP-1.
Benefits Beyond Weight Management
This acquisition goes beyond obesity. Click plans to leverage Better Therapeutics' assets to develop DTx solutions for type 2 diabetes, hypertension, hyperlipidemia and MASH. This holistic approach positions Click as a leader in DTx solutions for a wide range of cardiometabolic conditions.
“There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” said Rich DeNunzio, Chief Commercial Officer of Click Therapeutics. “The current one-size-fits-all approach to obesity management can be improved with innovative digital therapeutics that tailor treatments to individual needs, leading to improved patient outcomes and the opportunity to create data-driven contracting models with payers. By collaborating with pharma, payers, providers and patients to layer these capabilities onto the latest drugs, we can transform obesity care and enable our partners to succeed in what is soon to be a highly competitive market.”